1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 12 2.1 Therapy Area Introduction 12 2.2 Overview of Key Indications and Symptoms 12 2.2.1 Breast Cancer 13 2.2.2 Leukemia 15 2.2.3 Lymphoma 15 2.2.4 Melanoma 16 2.2.5 Non-Small Cell Lung Cancer 17 2.3 Diagnosis 18 2.3.1 Breast Cancer 18 2.3.2 Leukemia 18 2.3.3 Lymphoma 19 2.3.4 Melanoma 20 2.3.5 Non-Small Cell Lung Cancer 22 2.4 Etiology and Pathophysiology 23 2.4.1 Breast Cancer 26 2.4.2 Leukemia 27 2.4.3 Lymphoma 29 2.4.4 Melanoma 32 2.4.5 Non-Small Cell Lung Cancer 33 2.5 Epidemiology 37 2.5.1 Breast Cancer 38 2.5.2 Leukemia 38 2.5.3 Lymphoma 39 2.5.4 Melanoma 40 2.5.5 Non-Small Cell Lung Cancer 41 2.6 Prognosis 42 2.6.1 Breast Cancer 42 2.6.2 Leukemia 43 2.6.3 Lymphoma 44 2.6.4 Melanoma 44 2.6.5 Non-Small Cell Lung Cancer 45 2.7 Treatment 46 3 Key Marketed Products 49 3.1 Overview 49 3.2 Revlimid (lenalidomide) - Celgene 50 3.3 Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb 53 3.4 Keytruda (pembrolizumab) - Merck & Co. 55 3.5 Tecentriq (atezolizumab) - Roche 57 3.6 Darzalex (daratumumab) - Johnson & Johnson 59 3.7 Imfinzi (durvalumab) - AstraZeneca/Celgene 60 3.8 Gardasil/Gardasil 9 (human papillomavirus vaccine) - Merck & Co. 62 3.9 Pomalyst/Imnovid (pomalidomide) - Celgene 65 3.10 Yescarta (axicabtagene ciloleucel) - Gilead Sciences 66 3.11 Gazyva (obinutuzumab) - Roche 68 3.12 Yervoy (ipilimumab) - Bristol-Myers Squibb 69 3.13 Rituxan (rituximab) - Roche/Biogen 71 3.14 Kymriah (tisagenlecleucel) - Novartis 73 4 Pipeline Landscape Assessment 76 4.1 Overview 76 4.2 Pipeline Development Landscape 76 4.3 Molecular Targets in the Pipeline 79 4.4 Clinical Trials Landscape 82 4.4.1 Clinical Trial Failure Rates 83 4.4.2 Clinical Trial Duration 87 4.4.3 Clinical Trial Size 91 4.4.4 Cumulative Clinical Trial Size 94 4.5 Late-Stage Drugs of the Developmental Pipeline 99 4.5.1 Lisocabtagene maraleucel - Juno Therapeutics/Celgene 99 4.5.2 Durvalumab plus Tremelimumab - AstraZeneca 100 4.5.3 Tremelimumab - AstraZeneca 101 4.5.4 Cemiplimab - Regeneron/Sanofi 103 4.5.5 Epacadostat - Incyte Corp 104 4.5.6 Axalimogene filolisbac - Advaxis 106 5 Multi-scenario Market Forecast to 2024 108 5.1 Overall Market Size 108 5.2 Generic Penetration 112 5.3 Revenue Forecast by Molecular Target 113 5.3.1 Immune Checkpoint Proteins 114 5.3.2 Tumor Associated Antigens 114 5.3.3 Cytokine Signaling 117 5.3.4 HPV 118 6 Company Analysis and Positioning 119 6.1 Revenue and Market Share Analysis by Company 120 6.1.1 Celgene - Revlimid to Maintain Celgene’s Position as Market Leader 124 6.1.2 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth 126 6.1.3 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies 127 6.1.4 Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan 127 6.1.5 AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence 128 6.1.6 Johnson & Johnson - Darzalex Key to Strong Growth 130 6.1.7 Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue 131 6.1.8 AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024 132 6.1.9 Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta 133 6.1.10 Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters 134 6.2 Market and Pipeline Company Landscape 134 7 Strategic Consolidations 138 7.1 Licensing Deals 138 7.1.1 Deals by Region, Deal Value and Year 138 7.1.2 Deals by Indication and Deal Value 140 7.1.3 Deals by Stage of Development and Deal Value 141 7.1.4 Deals by Molecule Type, Molecular Target and Deal Value 142 7.1.5 Table for Licensing Deals with Disclosed Deal Value 143 7.2 Co-development Deals 154 7.2.1 Deals by Region, Deal Value and Year 154 7.2.2 Deals by Indication and Deal Value 156 7.2.3 Deals by Stage of Development and Deal Value 157 7.2.4 Deals by Molecule Type, Molecular Target and Deal Value 158 7.2.5 Table for Co-development Deals with Disclosed Deal Value 159 8 Appendix 164 8.1 References 164 8.2 Figures of All Clinical Stage Pipeline Products 177 8.3 Abbreviations 203 8.4 Disease List 205 8.5 Methodology 206 8.5.1 Coverage 206 8.5.2 Secondary Research 207 8.5.3 Market Size and Revenue Forecasts 207 8.5.4 Pipeline Analysis 207 8.5.5 Competitive Landscape 208 8.6 Contact Us 209 8.7 Disclaimer 209

1.1 List of Tables Table 1: Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018 13 Table 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016 37 Table 3: Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016 42 Table 4: Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016 43 Table 5: Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016 44 Table 6: Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016 44 Table 7: Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017 46 Table 8: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018 50 Table 9: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018 53 Table 10: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018 55 Table 11: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018 58 Table 12: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018 59 Table 13: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018 61 Table 14: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018 63 Table 15: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018 65 Table 16: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018 67 Table 17: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018 68 Table 18: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018 70 Table 19: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018 71 Table 20: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018 73 Table 21: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017-2024 110 Table 22: Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017-2024 120 Table 23: Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006-2018 143 Table 24: Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006-2018 1591.2 List of Figures Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018 34 Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016-2023 38 Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016-2023 39 Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016-2023 40 Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016-2023 41 Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016-2023 42 Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 50 Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006-2024 52 Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014-2024 55 Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014-2024 57 Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016-2024 59 Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015-2024 60 Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017-2024 62 Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006-2024 64 Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2024 66 Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018-2024 68 Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013-2024 69 Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011-2024 71 Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 73 Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017-2024 75 Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 76 Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018 77 Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 78 Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 79 Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018 81 Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 82 Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018 83 Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018 84 Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018 85 Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018 86 Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 87 Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018 88 Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018 89 Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018 90 Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 91 Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018 92 Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018 93 Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018 94 Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 95 Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018 96 Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018 97 Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018 98 Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018-2024 100 Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018-2024 101 Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018-2024 103 Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019-2024 104 Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020-2024 105 Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020-2024 107 Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017-2024 108 Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017-2024 112 Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 113 Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017-2024 114 Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017-2024 116 Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017-2024 117 Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017-2024 118